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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure that 
enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Afrikaans language. 
The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating centre was 
asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive patients seen 
in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical validation phase 
explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, floor/ceiling effects, 
internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity (convergent and 
discriminant validity). A total of 91 JIA patients (4.4% systemic JIA, 35.1% oligoarticular, 23.1% RF negative polyarthritis, 
37.4% other categories), and 98 healthy children were enrolled in one paediatric rheumatology centre. The JAMAR com-
ponents discriminated well healthy subjects from JIA patients. All JAMAR components revealed satisfactory psychometric 
performances. In conclusion, the Afrikaans version of the JAMAR is a valid tool for the assessment of children with JIA 
and is suitable for use both in routine clinical practice and in clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Afrikaans parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health-related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance, and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Afrikaans language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from April 2013 to 
August 2016. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. assessment of physical function (PF) using 15-items in 
which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10];
 2. rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. assessment of morning stiffness (present/absent);
 5. assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. rating of the level of disease activity on a 21-circle 
VAS;
 7. rating of disease status at the time of the visit (categori-
cal scale);
 8. rating of disease course from previous visit (categori-
cal scale);
 9. checklist of the medications the patient is taking (list 
of choices);
 10. checklist of side effects of medications;
 11. report of difficulties with medication administration 
(list of items);
 12. report of school/university/work problems caused by 
the disease (list of items);
 13. assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) sub-scales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated. [12–14];
 14. rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15. a question about satisfaction with the outcome of the 
illness (Yes/No) [15].
The JAMAR is available in three versions, one for parent 
proxy report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted in 
a similar language (i.e., Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy chil-
dren and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. In par-
ticular, we evaluated the following validity components: 
the first Likert assumption [mean and standard deviation 
(SD) equivalence]; the second Likert assumption or equal 
item-scale correlations (Pearson r: all items within a scale 
should contribute equally to the total score); third Lik-
ert assumption (item internal consistency or linearity for 
which each item of a scale should be linearly related to the 
total score that is 90% of the items should have Pearson 
r ≥ 0.4); floor/ceiling effects (frequency of items at lower 
and higher extremes of the scales, respectively); internal 
consistency, measured by the Cronbach’s alpha, interscale 
correlation (the correlation between two scales should be 
lower than their reliability coefficients, as measured by 
Cronbach’s alpha); test–retest reliability or intra-class 
correlation coefficient (reproducibility of the JAMAR 
repeated after 1 or 2 weeks); and construct validity in its 
two components: the convergent or external validity which 
examines the correlation of the JAMAR sub-scales with 
the 6 JIA core-set variables, with the addition of the parent 
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assessment of disease activity and pain by the Spearman’s 
correlation coefficients (r) [17] and the discriminant valid-
ity, which assesses whether the JAMAR discriminates 
between the different JIA categories and healthy children 
[18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Afrikaans parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Afrikaans JAMAR was fully cross-culturally adapted 
with two forward and two backward translations. The con-
cordance rate between the original standard English version 
of the JAMAR and the two back-translations was 91.9% 
(113/123 lines) for the parent version and 91.7% (110/120 
lines) for the child version.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range 80–100%). All the 120 lines of the 
patient version of the JAMAR were understood by at least 
80% of the children (median = 100%; range 80–100%). The 
text of the parent and patient JAMAR were left unmodified 
after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 91 JIA patients and 100 healthy children (total of 
191 subjects) were enrolled at the paediatric rheumatology 
clinic in Red Cross Children Hospital and Groote Schuur 
Hospital. Two healthy children did not give the consent to 
use their data.
In the 91 JIA subjects, the JIA categories were 4.4% with 
systemic JIA, 35.1% with oligoarthritis, 23.1% with RF 
negative polyarthritis, 6.6% with RF positive polyarthritis, 
6.6% with psoriatic arthritis, 15.4% with enthesitis related 
arthritis, and 8.8% with undifferentiated arthritis (Table 1).
A total of 168/189 (88.9%) subjects had the parent ver-
sion of the JAMAR completed by a parent (88 from parents 
of JIA patients and 80 from parents of healthy children). The 
JAMAR was completed by 151/168 (89.9%) mothers and 
17/168 (10.1%) fathers. The child version of the JAMAR 
was completed by 91/189 (48.1%) children age 7.3 or older.
Because of the presence of many official tongues in South 
Africa, the enrolled subjects have chosen different languages 
for the completion of their JAMAR through the data capture 
web system: 221/259 (85%) JAMAR questionnaires were 
completed in British English, in 8/259 (3%), the American 
English version of JAMAR was selected for completion, and 
in the remaining 30/259 (12%), the preferred language was 
Afrikaans.
Discriminant validity
The JAMAR results are presented in Table 1, including the 
scores [median (1st–3rd quartile)] obtained for the PF, the 
PhH, the PsH sub-scales, and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing “Results” section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did 
not allow to skip answers and input of null values. The 
response pattern for both PF and HRQoL was positively 
skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the differ-
ent HRQoL items except for item 1, whereas a reduced 
number of response choices was used for all the PF items 
except for items 1, 4, and 13. The mean and SD of the 
items within a scale were roughly equivalent for the PF 
and for the HRQoL items (data not shown). The median 
number of items marked as not applicable was 0% (0–0%) 
for the PF and 3% (1–3%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 84.1% (76.1–90.9%) for the PF 
items, 56.8% (53.4–63.6%) for the HRQoL physical health 
(PhH) items, and 60.2% (59.1–65.9%) for the HRQoL psy-
chosocial health (PsH) items. The median ceiling effect 
was 0% (0–1.1%) for the PF items, 4.5% (3.4–8%) for the 
HRQoL-PhH items, and 3.4% (2.3–3.4%) for the HRQoL-
PsH items. The median floor effect was 36.4% for the pain 
VAS, 36.4% for the disease activity VAS, and 37.5% for the 
well-being VAS. The median ceiling effect was 1.1% for the 
pain VAS, 4.6% for the disease activity VAS, and 4.6% for 
the well-being VAS.
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Table 1  Descriptive statistics (medians, first–third quartiles or absolute frequencies and %) for the 91 JIA patients
Data related to the JAMAR refer to the 88 JIA patients and to the 80 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD Medical Doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA Anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL Health-Related Quality of Life (total score ranges from 0 to 30), PhH physical health (total score ranges 
from 0 to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05 **p < 0.001 #p < 0.0001
Systemic Oligoarthritis RF − Polyar-
thritis
RF + Polyar-
thritis
Psoriatic 
Arthritis
Enthesitis 
related 
arthritis
Undifferenti-
ated arthritis
All JIA 
patients
Healthy
N = 4 N = 32 N = 21 N = 6 N = 6 N = 14 N = 8 N = 91 N = 98
Female 3 (75%) 20 (62.5%) 11 (52.4%) 4 (66.7%) 3 (50%) 10 (71.4%) 6 (75%) 57 (62.6%) 63 (64.3%)
Age at visit 5.4 (5.2–5.9) 6.9 (4.1–10.6) 12.3 
(7.8–13.7)
15.9 (14.6–
16.1)
9.8 (4.7–11.4) 13 (11.5–
15.5)
11 (6.8–15.4) 10.5 
(6.3–13.7)#
12 (8–15)*
Age at onset 3.4 (2.7–4.2) 3.5 (1.7–5.5) 7.9 (2.9–8.8) 10.6 
(9.7–12.9)
7.4 (4.4–9.3) 10.5 
(9.5–12.8)
9.2 (4.4–
10.2)
5.9 (2.9–9.8)#
Disease duration 1.9 (1.1–3.1) 2.2 (0.7–4.9) 4.4 (1.5–7.3) 5.2 (1.8–5.5) 1.7 (1.3–2.3) 2 (0.9–5.5) 2.1 (1.3–3.4) 2.2 (1.1–5.2)
ESR 11 (11–11) 9 (5–15) 6.5 (3.5–13) 12 (10–12) 2 (2–2) 15 (11–38) 18 (13–24) 10.5 (5–15)
MD VAS 
(0–10 cm)
0.3 (0–1.3) 1.8 (0.3–3.5) 2 (0–4) 2 (1–4) 2.5 (2–4) 3.5 (2–5.5) 2.8 (0.5–4) 2 (0.5–4)
No. swollen joints 0 (0–1) 1 (0–1.5) 1 (0–4) 4 (4–6) 2 (1–3) 0 (0–2) 1 (0–3) 1 (0–2)*
No. joints with 
pain
0 (0–1.5) 0 (0–1) 0 (0–5) 2.5 (1–8) 0 (0–2) 2 (2–4) 2 (0–3) 1 (0–3)**
No. joints with 
LOM
0.5 (0–1.5) 1 (0–2) 3 (1–10) 9.5 (3–33) 0 (0–1) 0 (0–2) 1 (0–2.5) 1 (0–3)**
No. active joints 0 (0–1.5) 1 (0–2) 1 (0–7) 4.5 (4–6) 2 (1–3) 0 (0–2) 1.5 (0–3) 1 (0–3)
Active systemic 
features
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
ANA status 0 (0%) 2 (6.3%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (2.2%)
Uveitis 0 (0%) 5/29 (17.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (25%) 7/85 (8.2%)
PF Total Score 0.5 (0–1) 1 (0–4.5) 1 (0–5) 0.5 (0–4.5) 4 (3–5) 4 (2–6) 4 (0–5) 1 (0–5) 0 (0–0)#
Pain VAS 0 (0–1.5) 0.8 (0–4.5) 0 (0–3.5) 1.8 (0–4.3) 3 (1–4) 4.5 (2–8) 2.5 (0.5–4.5) 1.5 (0–4.5)* 0 (0–0)#
Disease Activity 
VAS
2 (0–7) 1.3 (0–3) 1 (0–4) 1.5 (0–3.3) 5.5 (0–8) 4.5 (2.5–8) 1.3 (0–6.3) 1.5 (0–5)
Well-being VAS 0 (0–0.5) 0.8 (0–1.8) 1 (0–3.5) 1.8 (0–3.5) 1.3 (0–4.5) 4.5 (2.5–6) 2 (0–6.8) 1 (0–4.3)*
HRQoL-PhH 1.5 (0–3.5) 1 (0–4) 2 (0–4) 0.5 (0–3) 1 (1–6) 5 (3–6) 1 (1–4.5) 2 (0–5) 0 (0–0)#
HRQoL-PsH 1.5 (0–3.5) 1.5 (0–4) 2 (1–3) 0 (0–3) 2.5 (1–3) 3 (1–6) 2 (0–3) 2 (0–3.5) 0 (0–2)#
HRQoL Total 
Score
3.5 (1.5–5.5) 4 (0.5–8.5) 4 (1–7) 0.5 (0–6) 4.5 (1–8) 7 (5–12) 4 (1–6.5) 4 (1–8) 0 (0–2)#
Pain/swell. in > 1 
joint
1 (25%) 18 (56.3%) 10 (47.6%) 2/4 (50%) 4 (66.7%) 12/13 
(92.3%)
6 (75%) 53/88 
(60.2%)
2/80 (2.5%)#
Morning stiff-
ness > 15 min
0 (0%) 7 (21.9%) 6 (28.6%) 2/4 (50%) 2 (33.3%) 8/13 (61.5%) 3 (37.5%) 28/88 
(31.8%)
1/80 (1.3%)#
Subjective remis-
sion
2 (50%) 20 (62.5%) 9 (42.9%) 3/4 (75%) 4 (66.7%) 12/13 
(92.3%)
5 (62.5%) 55/88 
(62.5%)
In treatment 4 (100%) 29 (90.6%) 19 (90.5%) 4/4 (100%) 6 (100%) 13/13 (100%) 7 (87.5%) 82/88 
(93.2%)
Reporting side 
effects
0 (0%) 6/29 (20.7%) 6/19 (31.6%) 1/4 (25%) 4 (66.7%) 6/13 (46.2%) 5/7 (71.4%) 28/82 
(34.1%)*
Taking medica-
tion regularly
4 (100%) 28/29 (96.6%) 18/19 (94.7%) 4/4 (100%) 5 (83.3%) 10/13 
(76.9%)
7/7 (100%) 76/82 
(92.7%)
With problems 
attending school
0 (0%) 4/20 (20%) 1/11 (9.1%) 0 (0%) 1/4 (25%) 4/8 (50%) 0 (0%) 10/54 
(18.5%)
2/77 (2.6%)*
Satisfied with dis-
ease outcome
3 (75%) 24 (75%) 17 (81%) 3/4 (75%) 2 (33.3%) 5/13 (38.5%) 2 (25%) 56/88 
(63.6%)*
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Equal item‑scale correlations (second Likert 
assumption)
Pearson item-scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the 
PF items, with the exception of PF items 7 and 15, and for 
70% of the HRQoL items, with the exception of HRQoL 
items 1, 5, and 8.
Item internal consistency (third Likert assumption)
Pearson item-scale correlations were ≥ 0.4 for 80% of items 
of the PF (except for PF items 7, 13, and 15) and 90% of 
items of the HRQoL (except for HRQoL item 8).
Table 2  Main psychometric characteristics between the parent and child versions of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiophatic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL Health-Related Quality of Life, PhH Physical Health, PsH Psychosocial Health, PF-LL PF-lower limbs, PF-HW PF-hand and 
wrist, PF-US PF-upper segment
Parent N = 88/168 Child N = 52/91
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 84.1% 82.7%
 HRQoL-PhH 56.8% 59.6%
 HRQoL-PsH 60.2% 59.6%
 Pain VAS 36.4% 19.2%
 Disease activity VAS 36.4% 28.9%
 Well-being VAS 37.5% 30.8%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL-PhH 4.5% 3.8%
 HRQoL-PsH 3.4% 0.0%
 Pain VAS 1.1% 1.9%
 Disease activity VAS 4.6% 0.0%
 Well-being VAS 4.6% 0.0%
Items with equivalent item-scale correlation 87% for PF, 70% for HRQoL 100% for PF, 90% for HRQoL
Items with item-scale correlation ≥ 0.4 80% for PF, 90% for HRQoL 100% for PF, 80% for HRQoL
Cronbach’s alpha
 PF-LL 0.85 0.85
 PF-HW 0.71 0.80
 PF-US 0.55 0.78
 HRQoL-PhH 0.85 0.80
 HRQoL-PsH 0.76 0.72
Items with item-scale correlation lower than the Cronbach alpha 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Test–retest intra-class correlation
 PF total score 0.93 0.98
 HRQoL-PhH 0.92 1.00
 HRQoL-PsH 0.90 0.79
Spearman correlation with JIA core-set variables, median
 PF 0.4 0.3
 HRQoL-PhH 0.3 0.4
 HRQoL-PsH 0.1 0.3
 Pain VAS 0.2 -0.04
 Disease activity VAS 0.2 0.2
 Well-being VAS 0.2 0.2
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.85 for PF-LL, 0.71 for PF-HW, and 
0.55 for PF-US. Cronbach’s alpha was 0.85 for HRQoL-PhH 
and 0.76 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 5 JIA patients, by re-administer-
ing both versions (parent and child) of the JAMAR after a 
median of 0 day (0–2 days). The intra-class correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC = 0.93). The ICC for the HRQoL-PhH 
and for the HRQoL-PsH showed an almost perfect reproduc-
ibility (ICC = 0.92 and ICC = 0.90, respectively).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.1 to 0.5 
(median = 0.4). The PF total score best correlation was 
observed with the parent assessment of pain (r = 0.5, 
p < 0.001). For the HRQoL, the median correlation of the 
PhH with the JIA core set of outcome variables ranged 
from 0.1 to 0.6 (median = 0.3), whereas for the PsH ranged 
from − 0.2 to 0.3 (median = 0.1). The PhH showed the best 
correlation with the parent’s assessment of pain (r = 0.7, 
p < 0.001) and the PsH with the physician global assessment 
of well-being (r = 0.4, p < 0.001). The median correlations 
between the pain VAS, the well-being VAS, and the dis-
ease activity VAS and the physician-centred and laboratory 
measures were 0.2 (0.02–0.4), 0.2 (0–0.3), 0.2 (0.1–0.3), 
respectively.
Discussion
In this study, the Afrikaans version of the JAMAR was fully 
cross-culturally adapted from the original standard English 
version with two forward and two backward translations. 
According to the results of the validation analysis, the Afri-
kaans parent and patient versions of the JAMAR possess 
satisfactory psychometric properties. The disease-specific 
components of the questionnaire discriminated well between 
patients with JIA and healthy controls.
Psychometric performances were good for all domains 
of the JAMAR with some exceptions: 3 PF items (“open 
and close fists”, “turn head and look over shoulders” and 
“bite a sandwich or an apple”) and 1 HRQoL item (“have 
trouble getting alone with other children”) showed a lower 
items internal consistency. Furthermore, the overall internal 
consistency for PF-US was poor.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core-set 
parameters ranged from very weak to moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, which 
suggests that children are equally reliable proxy report-
ers of their disease and health status as their parents. The 
JAMAR is aimed to evaluate the side effects of medications 
and school attendance, which are other dimensions of daily 
life that were not previously considered by other HRQoL 
tools. This may provide useful information for intervention 
and follow-up in health care. In conclusion, the Afrikaans 
version of the JAMAR was found to have satisfactory psy-
chometric properties and it is, thus, a reliable and valid tool 
for the multidimensional assessment of children with JIA.
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